Reactivation of hepatitis in a bladder cancer patient receiving chemotherapy.
Reactivation of hepatitis is a serious complication of chemotherapy in hepatitis B virus (HBV) carriers. There are many reports of this in lymphoma patients but few in urological cancer patients. A 59-year-old woman with bladder cancer who was an HBV carrier developed severe liver dysfunction after 2 cycles of chemotherapy. The diagnosis was reactivation of hepatitis. She improved with administration of lamivudine with a steroid and is currently well without disease. Care should be taken about the risk of reactivation when performing chemotherapy in HBV carriers and prophylaxis by lamivudine should be considered.
Higashiyama
Hiroshi
H
Department of Renal and Genito-urinary Surgery, Graduate School of Medicine, Hokkaido University, Kita-15, Nishi-7, Sapporo, Japan.
Harabayashi
Toru
T
Shinohara
Nobuo
N
Chuma
Makoto
M
Hige
Shuhei
S
Nonomura
Katsuya
K
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D015251:Epirubicin / Q000009:adverse effects*; D005260:Female; D006509:Hepatitis B / Q000139:chemically induced*; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects*; D008875:Middle Aged; D012008:Recurrence; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D015251:Epirubicin; D002945:Cisplatin; D008727:Methotrexate